



University of  
BRISTOL



61<sup>ST</sup> ERA  
CONGRESS  
STOCKHOLM & VIRTUAL  
MAY 23-26, 2024

## **Sparsentan has direct effects on the glomerular capillary wall to attenuate increased permeability after exposure to nephrotic syndrome plasma**

**Michael Crompton**, Judy J. Watson, Elizabeth Colby, Wilmelenne Clapper, Celia P. Jenkinson, Bruce Hendry, Radko Komers, Moin A. Saleem, Gavin I. Welsh, Rebecca R. Foster, Simon C. Satchell

Bristol Renal, Bristol Heart Institute, Translational Health Science,  
University of Bristol, BS1 3NY

# Endothelin type A ( $ET_A R$ ) and angiotensin II type 1 ( $AT_1 R$ ) receptors may regulate glomerular endothelial glycocalyx (eGlx)




**ET-1**, endothelin 1  
**ANG II**, angiotensin II

Daehn et al., 2014, PMID: 24590287; Ebefors et al., 2019, PMID: 31402170;  
Kuwabara et al., 2010, PMID: 20526760; Crompton et al., 2023, PMID: 36749631

# Sparsentan is a single molecule, dual ET<sub>A</sub>R and AT<sub>1</sub>R antagonist and therefore has potential to protect glomerular eGlx

## Sparsentan


- Approved in US and EU for the reduction of proteinuria in adults with IgA nephropathy\*
- Under clinical development for FSGS





ET-1, endothelin 1  
ANG II, angiotensin II

\*accelerated approval in US; conditional approval in EU


# AIM: Can sparsentan protect the eGlx and maintain the glomerular filtration barrier in rat glomeruli exposed to human nephrotic syndrome (NS) plasma?





# Our validated glomerular permeability assay directly measures the albumin permeability ( $Ps'_{\text{alb}}$ ) of capillary loops within individually trapped glomeruli




AF488-BSA



Decline in fluorescence intensity of labelled albumin (ROI1) over time





# Human NS plasma increased glomerular albumin permeability in rat glomeruli




$Ps'_{alb}$ , albumin permeability. # of animals (# of glomeruli). Mean  $\pm$  SEM; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$

# Human NS plasma increased glomerular albumin permeability in rat glomeruli




$Ps'_{alb}$ , albumin permeability. # of animals (# of glomeruli). Mean  $\pm$  SEM; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$

# Sparsentan dose-dependently protected against increased glomerular albumin permeability resulting from human NS plasma



Mean  $\pm$  SEM; \*, p < 0.05; \*\*, p < 0.01; \*\*\*, p < 0.001. +, P-value vs. Remission+Vehicle

# Sparsentan prevented eGlx damage in rat glomeruli exposed to human NS plasma





LEL (*Lycopersicon esculentum* Lectin) - luminal glomerular eGlx

R18 (Octadecyl Rhodamine B Chloride) – cell membrane label



DAPI – nuclear label

Scale bar = 10  $\mu$ m  
MA-SP-24-0066 05/2024


# Sparsentan dose-dependently prevented eGlx damage in rat glomeruli exposed to human NS plasma



# The effect of sparsentan in preventing the NS-induced increase in glomerular permeability is correlated with protection from eGlx loss




- ◊ Remission + Vehicle
- ◆ Relapse + Vehicle
- Relapse + Sparsentan (10  $\mu\text{M}$ )
- ◆ Relapse + Sparsentan (1  $\mu\text{M}$ )
- Relapse + Sparsentan (0.1  $\mu\text{M}$ )



# Sparsentan preserved glomerular eGlx and protected glomeruli from increased permeability following exposure to human NS plasma

## SUMMARY

- Dual antagonism of  $ET_A R$  and  $AT_1 R$ , with sparsentan, preserved the glomerular eGlx resulting in normalised glomerular permeability following incubation with NS plasma
- The direct action of sparsentan on the GFB could help maintain barrier integrity in NS, via glycocalyx protection



# Acknowledgements



Judy J. Watson  
Elizabeth Colby  
Moin A. Saleem  
Gavin I. Welsh  
Rebecca R. Foster  
Simon C. Satchell

Bristol Renal  
Wolfson Bioimaging Facility

[m.crompton@bristol.ac.uk](mailto:m.crompton@bristol.ac.uk)

**This work was funded by  
Travere Therapeutics, Inc.**

Wilmelenne Clapper  
Celia P. Jenkinson  
Bruce Hendry  
Radko Komers



*To obtain a PDF of this presentation, please scan the Quick Response (QR) code. No personal information is stored.*